Funding therapy a 'no-brainer'

Posted 13 December 2024 AM

Australian researchers have demonstrated an adoptive immunotherapy that targets out-of-control viral infections in critically-ill immunocompromised patients, saving dozens of lives, with funding production of the therapy labelled a "no-brainer".

Developed by QIMR Berghofers Professor Rajiv Khanna and his team, the therapy is currently being supplied under the TGA's Special Access Scheme, which allows patients to access unapproved therapeutic goods as a last resort for treatment.

To see the whole article, please login